loading
Apellis Pharmaceuticals Inc stock is traded at $27.97, with a volume of 1.82M. It is up +1.27% in the last 24 hours and up +40.62% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$27.62
Open:
$27.84
24h Volume:
1.82M
Relative Volume:
0.75
Market Cap:
$3.53B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-13.78
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+0.79%
1M Performance:
+40.62%
6M Performance:
+1.64%
1Y Performance:
-28.54%
1-Day Range:
Value
$27.43
$28.25
1-Week Range:
Value
$26.23
$28.25
52-Week Range:
Value
$16.10
$41.94

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name
Name
Apellis Pharmaceuticals Inc
Name
Phone
617-977-5700
Name
Address
100 FIFTH AVENUE, WALTHAM, KY
Name
Employee
710
Name
Twitter
@ApellisPharma
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
APLS's Discussions on Twitter

Compare APLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
27.97 3.45B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date Action Analyst Rating Change
May-09-25 Downgrade BofA Securities Buy → Neutral
May-09-25 Downgrade Raymond James Strong Buy → Outperform
Apr-29-25 Initiated Cantor Fitzgerald Overweight
Dec-17-24 Downgrade Goldman Buy → Neutral
Nov-21-24 Initiated Morgan Stanley Equal-Weight
Oct-25-24 Initiated RBC Capital Mkts Sector Perform
Oct-16-24 Initiated Scotiabank Sector Outperform
Oct-16-24 Initiated William Blair Outperform
May-31-24 Initiated Piper Sandler Neutral
Feb-05-24 Upgrade Jefferies Hold → Buy
Dec-14-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-09-23 Initiated Goldman Buy
Nov-02-23 Initiated Mizuho Neutral
Oct-06-23 Upgrade JP Morgan Neutral → Overweight
Sep-15-23 Upgrade Wells Fargo Equal Weight → Overweight
Aug-29-23 Reiterated Citigroup Buy
Aug-03-23 Downgrade JP Morgan Overweight → Neutral
Aug-01-23 Downgrade BofA Securities Buy → Neutral
Jan-03-23 Downgrade Wells Fargo Overweight → Equal Weight
Nov-10-22 Downgrade Jefferies Buy → Hold
Jul-19-22 Initiated H.C. Wainwright Buy
Jun-17-22 Resumed Stifel Buy
Apr-14-22 Downgrade ROTH Capital Neutral → Sell
Dec-08-21 Initiated Wells Fargo Overweight
Nov-29-21 Downgrade ROTH Capital Buy → Neutral
Sep-10-21 Reiterated BMO Capital Markets Outperform
Sep-10-21 Reiterated Credit Suisse Neutral
Sep-10-21 Reiterated Needham Buy
Sep-10-21 Reiterated Oppenheimer Outperform
Sep-10-21 Downgrade Wedbush Outperform → Neutral
Aug-19-21 Initiated Jefferies Buy
Aug-19-21 Upgrade Wedbush Neutral → Outperform
May-21-21 Initiated UBS Buy
Apr-16-21 Initiated Goldman Buy
Nov-19-20 Initiated Needham Buy
Sep-01-20 Initiated Stifel Buy
Jul-20-20 Initiated ROTH Capital Buy
Jun-17-20 Initiated BTIG Research Neutral
Apr-01-20 Initiated Raymond James Strong Buy
Mar-31-20 Initiated BMO Capital Markets Outperform
Mar-11-20 Upgrade Wedbush Underperform → Neutral
Jan-07-20 Initiated SVB Leerink Mkt Perform
Dec-19-19 Initiated BofA/Merrill Buy
Nov-22-19 Initiated Wedbush Underperform
Nov-05-19 Initiated Credit Suisse Neutral
Aug-01-19 Reiterated Cantor Fitzgerald Overweight
Jul-12-19 Upgrade JP Morgan Neutral → Overweight
Mar-29-19 Initiated Robert W. Baird Outperform
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Jul-30-18 Upgrade B. Riley FBR Neutral → Buy
May-24-18 Initiated Cantor Fitzgerald Overweight
Apr-12-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Feb-08-18 Initiated B. Riley FBR, Inc. Buy
View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

pulisher
Aug 20, 2025

Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN

Aug 20, 2025
pulisher
Aug 18, 2025

Signal strength of Apellis Pharmaceuticals Inc. stock in tech scanners2025 Trade Ideas & Fast Gain Stock Tips - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Analyzing drawdowns of Apellis Pharmaceuticals Inc. with statistical toolsJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Chart based exit strategy for Apellis Pharmaceuticals Inc.Quarterly Profit Report & AI Forecasted Entry and Exit Points - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Apellis Pharmaceuticals Inc. Breaks Below Key Support Level2025 Price Momentum & Weekly Consistent Profit Watchlists - newsimpact.co.kr

Aug 18, 2025
pulisher
Aug 17, 2025

How to use Fibonacci retracement on Apellis Pharmaceuticals Inc.Weekly Risk Summary & High Yield Equity Trading Tips - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Will Apellis Pharmaceuticals Inc. stock benefit from interest rate changes2025 Top Gainers & Daily Volume Surge Signals - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

How to track smart money flows in Apellis Pharmaceuticals Inc.2025 Institutional Moves & Weekly High Potential Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Is Apellis Pharmaceuticals Inc. reversing from oversold territory2025 Dividend Review & Fast Entry Momentum Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Can momentum traders help lift Apellis Pharmaceuticals Inc.2025 Short Interest & Accurate Technical Buy Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Apellis Pharmaceuticals Inc. stock momentum explainedPortfolio Growth Summary & Intraday High Probability Setup Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Chart overlay techniques for tracking Apellis Pharmaceuticals Inc.Weekly Investment Report & Community Verified Swing Trade Signals - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Tick level data insight on Apellis Pharmaceuticals Inc. volatilityWeekly Gains Report & Community Verified Trade Alerts - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Can a trend reversal in Apellis Pharmaceuticals Inc. lead to recoveryChart Signals & Stepwise Swing Trade Plans - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

What makes Apellis Pharmaceuticals Inc. stock price move sharplyIndex Update & Safe Swing Trade Setup Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

Apellis Pharmaceuticals Inc. Consolidation Zone May Signal Accumulation2025 Volume Leaders & Low Risk Profit Maximizing Plans - classian.co.kr

Aug 15, 2025
pulisher
Aug 14, 2025

Warm Autoimmune Hemolytic Anemia Market to Observe Significant Growth During the Forecast Period | Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation - Barchart.com

Aug 14, 2025
pulisher
Aug 14, 2025

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli’s New Approval (APLS) - Seeking Alpha

Aug 14, 2025
pulisher
Aug 13, 2025

Watch for Trend Continuation in Apellis Pharmaceuticals Inc. Next Week2025 Major Catalysts & Risk Controlled Swing Trade Alerts - beatles.ru

Aug 13, 2025
pulisher
Aug 13, 2025

Apellis Pharmaceuticals (APLS) Surges 10.27% on FDA Approval Momentum and Strategic Deals - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week - Insider Monkey

Aug 13, 2025
pulisher
Aug 13, 2025

Apellis Pharmaceuticals' Stock Surges 27.70% This Week Following FDA Approval, Q2 2025 Financial Results, and Capped Royalty Purchase Agreements - AInvest

Aug 13, 2025
pulisher
Aug 11, 2025

Published on: 2025-08-12 03:12:35 - beatles.ru

Aug 11, 2025
pulisher
Aug 11, 2025

Trading Bots Trigger Alerts on Apellis Pharmaceuticals Inc. ActivityBreakout Momentum Picks With Protection Outlined - beatles.ru

Aug 11, 2025
pulisher
Aug 10, 2025

A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $20 to $57 - 富途牛牛

Aug 10, 2025
pulisher
Aug 10, 2025

11 Best Short-Term Stocks to Invest in - Insider Monkey

Aug 10, 2025
pulisher
Aug 08, 2025

Apellis wins FDA label expansion for Empaveli in rare kidney disorders - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Fierce Biotech Layoff Tracker 2025: Tune, Bicycle let go of 25% of staff - Fierce Biotech

Aug 08, 2025
pulisher
Aug 07, 2025

Apellis Pharmaceuticals' Empaveli Faces Market Challenges and Physician Preferences - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Hold Rating for Apellis Pharmaceuticals’ Empaveli Amid Market Challenges and Physician Preferences - TipRanks

Aug 07, 2025
pulisher
Aug 06, 2025

Apellis Pharmaceuticals (APLS) Sees Target Price Raised by Citig - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 05, 2025

Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS) and Akero Therapeutics (AKRO) - The Globe and Mail

Aug 05, 2025
pulisher
Aug 05, 2025

Published on: 2025-08-04 22:37:11 - beatles.ru

Aug 05, 2025
pulisher
Aug 04, 2025

APLS: JP Morgan Raises Price Target to $37, Maintains Overweight Rating | APLS Stock News - GuruFocus

Aug 04, 2025
pulisher
Aug 04, 2025

Why Apellis Pharmaceuticals Shares Are Gaining Attention - TipRanks

Aug 04, 2025
pulisher
Aug 03, 2025

Apellis Pharmaceuticals Inc. Stock Analysis and ForecastInvest smarter with actionable stock recommendations - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug - MSN

Aug 03, 2025
pulisher
Aug 03, 2025

Apellis’ EMPAVELI Approved by FDA for Rare Kidney Diseases - msn.com

Aug 03, 2025
pulisher
Aug 03, 2025

When is Apellis Pharmaceuticals Inc. stock expected to show significant growthBuild a portfolio with strong long-term growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How many analysts rate Apellis Pharmaceuticals Inc. as a “Buy”Exceptional profit potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Apellis Pharmaceuticals Inc. a growth stock or a value stockFree Stock Movement Tracking - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is Apellis Pharmaceuticals Inc. company’s balance sheetBuild wealth steadily with proven investment techniques - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is Apellis Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough growth with proven strategies - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Apellis Pharmaceuticals Inc. stockConsistent triple-digit returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Apellis Pharmaceuticals Inc. stock higher in 2025High-octane investment gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What drives Apellis Pharmaceuticals Inc. stock priceCapitalize on market trends before they peak - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Apellis Pharmaceuticals Inc. stockFree Stock Movement Tracking - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Apellis Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock exclusive stock market forecasts - Jammu Links News

Aug 03, 2025

Apellis Pharmaceuticals Inc Stock (APLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):